1Kappe R.Antifungal Activity of the New Azole UK-109,406.Mycosis,1999,42(s2):83 被引量：1
2Murphy M,Bernard EM,Ishimaru T,et al.Activity of Viroconazole(UK -109,496) against Clinical Isolates of Aspergillus Species and Its Effectiveness in the Experimental Model of Invasive Pulmonary Aspergillosis.Antimicrob Agents Chemother,1999,44(10):1463 被引量：1
3Uzun O,Arikan S,Kocagoz S,et al.Susceptibility Testing of Voriconazole,Fluconazole,Itraconazole and Amphotericin B against Yeast Isolates in A Turkish University Hospital and Effect of Time of Reading.Diagn Microbiol Infect Dis,2000,38:101 被引量：1
4Pfaller M A,Messer S A,Hollis R J,et al.In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents Bms -207147,Sch 56592,and Voriconazole.Antimicrob Agents Chemother,1998,42:3242 被引量：1
6Diekema D J,Messer S A,Hikkus R J,et al.Activities of caspofungin,itraconazole,posaconazole,ravuconazole,voriconazole,and amphotericin B against 448 recent clinical isolates of filamentous fungi.J Clin Microbiol,2003,47 (12):3976 被引量：1
7Denng D W,R Baud P,Mlpied N,et al.Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.Clin Infect Dis,2002,34(5):563 被引量：1
8Murphy M,Bernard E M,Ishimaru T,et al.Activity of Viroconazole(UK-109,496) against Clinical Isolates of Aspergillus Species and Its Effectiveness in the Experimental Model of Invasive Pulmonary Aspergillosis.Antimicrob Agents Chemother,1999,44(10):1463 被引量：1
9Purkins L,Wood N,Ghahramani P,et al.Pharmacokinetics and Safety of Voriconazole Following Intravenous to Oral-Dose Escalation Regimens.Antimicrob Agents Chenother,2002,46(8):2546 被引量：1
10Herbrecht R,Denning D W,Patterson T F,et al.Voriconazole Versus Amphotericin B for Primary Therapy of Invasive Aspergillosis.N Engl J Med,2002,347 (6):408 被引量：1
二级参考文献11
1Ghannoum MA,Kuhn DM.Voriconazole-better chances for patienes with invasibve mycoses[J].Eur J Med Res,2002,31 (5):242-256. 被引量：1
2Berke I,Tiemo PMJr.Comparison of efficacy and cost-effectiveness of Biomic video and Vitek antimicrobial snsceptibility test syste for use in the clinical microbiology laboratory[J].J Clin Microbil,1996,34(8):1980-1984. 被引量：1
3Rogers TR.Antifungal drug resistance:does it matter[J].Int J Infect Dis,2002,6(1):S47-53. 被引量：1
4Beck-Sague C,Jarvis WR.Secular trends in the epidemiology of nosocomial fungal infections in the United States,1980-1990[J].J Infect Dis,1993,167(5):1247-1251. 被引量：1
6Duong M,Ouellet N,Simard M,et al.Kinetic study of host defense and inflammatory response to Aspergillus fumigatus insteroid - induced immunosuppressed mice[].The Journal of Infectious Diseases.1998 被引量：1
7Kieren AM,Thomas P,David D. et al.Aspergillosis: Pathogenesis, clinical manifestations, and therapy[].Infectious Disease Clinics of North America.2002 被引量：1
8Walsh T,Pappas P,Winston D,et al.Voriconazole versus Liposomal amphotericin B for empirical antifungal therapy of persisten ferbrile neutropenic patients : a randomized international,multi- center trial[].The New England Journal of Medicine.2002 被引量：1
9Hebreeht R,Denning DW,Patterson TF,et al.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[].The New England Journal of Medicine.2002 被引量：1
10Johnson LB,Kauffman CA.Voriconazole: A new triazole antifungal agent[].Clinical Infectious Diseases.2003 被引量：1
